Immune globulin and vaccine therapy to prevent hepatitis A infection.

Abstract

The hepatitis A virus is usually transmitted person-to-person due to fecal-oral exchange of virus. Approximately 30,000 infections are reported each year in the United States, with the actual incidence being much greater. Prophylaxis with immune globulin has had a minimal impact on the overall incidence of hepatitis A. The recent availability and proven efficacy of a hepatitis A vaccine offers the hope that the incidence of infection may be substantially reduced. Pre- and postexposure prophylaxis should be targeted to individuals at increased risk of either acquiring infection, transmitting infection, or developing fulminant hepatitis, or to help control epidemics. This article reviews the current literature and discusses recommendations for pre- and postexposure prophylaxis against hepatitis A virus.

• Authors: M J Levy, J L Herrera, J A DiPalma
• Journal: The American journal of medicine (Am J Med) Vol. 105 Issue 5 Pg. 416-23 (Nov 1998) ISSN: 0002-9343 [Print] United States
• PMID: 9831426 (Publication Type: Journal Article, Review)

Topics

• Adult
• Child
• Hepatitis A (prevention & control)
• Humans
• Immunization, Passive
• Immunotherapy, Active